**Core Concept**
ADP (Adenosine Diphosphate) inhibitors are a class of medications that prevent platelet activation and aggregation by inhibiting the P2Y12 receptor, which is a subtype of ADP receptor. This leads to a decrease in thrombus formation and a subsequent reduction in the risk of myocardial infarction and stroke.

**Why the Correct Answer is Right**
The correct answer is a medication that does not inhibit ADP receptors. ADP inhibitors, such as ticagrelor, clopidogrel, and prasugrel, bind to the P2Y12 receptor and prevent ADP from binding, thereby inhibiting platelet activation. The correct answer is a medication that works through a different mechanism.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is an ADP receptor inhibitor, which means it works by blocking the ADP receptor and preventing platelet activation.
**Option B:** This option is also an ADP receptor inhibitor, similar to option A.
**Option C:** This option is an ADP receptor inhibitor, which means it works by blocking the ADP receptor and preventing platelet activation.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that ADP inhibitors are a key class of medications used to prevent platelet activation and aggregation, and they are commonly used in patients with cardiovascular disease.

**Correct Answer: D.**